Fudan developed a cardiac dying emergency device

Release date: 2009-03-16





In China, there are 550,000 sudden cardiac deaths each year, and the survival rate of sudden cardiac death is less than 1%. How do people cope with this irreversible disease? Recently, it was learned from the Academician Salon of the Shanghai Academician Center that in developed countries, the “extracorporeal defibrillator” (AED) has been set up in public places, which can effectively reduce the death rate of sudden cardiac death. However, there is no similar domestic equipment in China. Fudan University experts said that they have developed an AED with independent intellectual property rights, hoping to arouse the interest of enterprises and industrialize them as soon as possible.

Prof. Fang Zuxiang from the Institute of Biomedical Instruments of Fudan University said that since 2002, Fudan University and the First Affiliated Hospital of Suzhou University have jointly carried out AED research and development, and all software and hardware are designed independently. The project passed the identification of scientific and technological achievements at the end of 2006. Fang Zuxiang said that the prototypes they have developed have completed more than 20 animal experiments and declared 9 national patents, but unfortunately they have not achieved industrialization. At present, the AEDs used in China are all imported, and the price of each is 60-80,000 yuan. If the prototype of self-developed is industrialized, the selling price is estimated to be only 8,000-10,000 yuan.

At present, AED has become popular in public places in Europe, America, and Japan, and is entering the family of patients with general heart disease. Fang Zuxiang said that Chinese enterprises still don't know enough about AED, so that because there is no domestic AED, they can only import from abroad at high prices during the Olympics and World Expo. “I hope that Shanghai enterprises can produce AEDs and let them enter public places, hospitals and families in China, and benefit the lives of ordinary people.”

Bulk of varicella vaccine,semi-Finished Products.It has good safety with low ratio in adverse reaction. And it has been exported to Bangladesh. 

In 2008, BCHT successfully launched its product Varicella Vaccine, Live in China. In the following years, BCHT continuously committed to improving the product and led in 2010 removal of gelatin from adjuvant and extended the vaccine shelf-life up to 36 months which is the longest one in the world in 2011. And it has the following qualities.


Varicella Vaccine

Final Bulk

Biotechnology Bioproducts Preventive,Final Bulk Medicine Preventive,Final Bulk Pharmaceutical Preventive,Vaccine Biological Products Preventive

Changchun BCHT Biotechnology Co. , https://www.ccbcht.com